NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Company profile
Ticker
NEO
Exchange
Website
CEO
Douglas M. Van Oort
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Digipath • 20/20 GeneSystems ...
Former names
AMERICAN COMMUNICATIONS ENTERPRISES INC
SEC CIK
Corporate docs
Subsidiaries
Clarient Diagnostic Services, Inc. • Clarient, Inc. • Cynogen, Inc. • Genesis Acquisition Holdings Corp. • Genoptix, Inc. • Inivata Limited, UK Limited Company • Inivata, Inc., Delaware Corporation • Minuet Diagnostics, Inc. • NeoGenomics Bioinformatics, Inc. • NeoGenomics Europe, SA ...
IRS number
742897368
NEO stock data
Analyst ratings and price targets
Current price
Average target
$15.40
Low target
$12.00
High target
$18.00
Needham
Upgraded
$15.00
Piper Sandler
Maintains
$18.00
Raymond James
Maintains
$12.00
Morgan Stanley
Maintains
$17.00
SVB Leerink
Maintains
$15.00
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
23 Jan 23
8-K
NeoGenomics Announces Chief Financial Officer Transition
5 Dec 22
S-8
Registration of securities for employees
5 Dec 22
8-K
Departure of Directors or Certain Officers
18 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
NeoGenomics Reports Third Quarter 2022 Results
8 Nov 22
8-K
Departure of Directors or Certain Officers
7 Nov 22
8-K
Departure of Directors or Certain Officers
20 Oct 22
S-8
Registration of securities for employees
12 Aug 22
8-K
Departure of Directors or Certain Officers
12 Aug 22
Transcripts
NEO
Earnings call transcript
2022 Q2
9 Aug 22
NEO
Earnings call transcript
2022 Q1
27 Apr 22
NEO
Earnings call transcript
2021 Q4
23 Feb 22
NEO
Earnings call transcript
2021 Q3
4 Nov 21
NEO
Earnings call transcript
2021 Q2
6 Aug 21
NEO
Earnings call transcript
2021 Q1
6 May 21
NEO
Earnings call transcript
2020 Q4
24 Feb 21
NEO
Earnings call transcript
2020 Q3
27 Oct 20
NEO
Earnings call transcript
2020 Q2
28 Jul 20
NEO
Earnings call transcript
2020 Q1
28 Apr 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 266.13 mm | 266.13 mm | 266.13 mm | 266.13 mm | 266.13 mm | 266.13 mm |
| Cash burn (monthly) | 5.84 mm | 6.47 mm | 13.21 mm | 14.84 mm | 5.42 mm | 6.84 mm |
| Cash used (since last report) | 24.44 mm | 27.08 mm | 55.31 mm | 62.12 mm | 22.71 mm | 28.64 mm |
| Cash remaining | 241.68 mm | 239.05 mm | 210.82 mm | 204.01 mm | 243.41 mm | 237.48 mm |
| Runway (months of cash) | 41.4 | 37.0 | 16.0 | 13.8 | 44.9 | 34.7 |
Institutional ownership, Q3 2022
83.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 238 |
| Opened positions | 36 |
| Closed positions | 36 |
| Increased positions | 72 |
| Reduced positions | 84 |
| 13F shares | Current |
|---|---|
| Total value | 912.07 mm |
| Total shares | 105.95 mm |
| Total puts | 120.70 k |
| Total calls | 591.00 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 21.11 mm | $181.75 mm |
| Vanguard | 13.17 mm | $113.43 mm |
| Brown Advisory | 6.18 mm | $53.22 mm |
| JHG Janus Henderson | 5.96 mm | $51.33 mm |
| Wellington Management | 3.21 mm | $27.63 mm |
| First Light Asset Management | 2.72 mm | $23.42 mm |
| GS Goldman Sachs | 2.65 mm | $22.82 mm |
| T. Rowe Price Investment Management | 2.57 mm | $22.12 mm |
| Geode Capital Management | 2.35 mm | $20.23 mm |
| Emerald Advisers | 2.14 mm | $18.42 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Jan 23 | Melody Harris | Common Stock | Grant | Acquire A | No | No | 0 | 108,225 | 0.00 | 108,225 |
| 1 Jan 23 | Melody Harris | Stock Option Common Stock | Grant | Acquire A | No | No | 9.24 | 201,613 | 1.86 mm | 201,613 |
| 31 Dec 22 | Cynthia J Dieter | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 959 | 0.00 | 30,762 |
| 31 Dec 22 | Vishal Sikri | Common Stock | Acquire L | No | No | 7.04 | 225 | 1.58 k | 148,680 | |
| 5 Dec 22 | Jeffrey Scott Sherman | Common Stock | Grant | Acquire A | No | No | 0 | 89,206 | 0.00 | 133,809 |
| 5 Dec 22 | Jeffrey Scott Sherman | Common Stock | Grant | Acquire A | No | No | 0 | 44,603 | 0.00 | 44,603 |
| 5 Dec 22 | Jeffrey Scott Sherman | Stock Option Common Stock | Grant | Acquire A | No | No | 11.62 | 249,169 | 2.90 mm | 249,169 |
News
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
1 Feb 23
Analyst Expectations for NeoGenomics's Future
1 Feb 23
Needham Upgrades NeoGenomics to Buy, Announces $15 Price Target
1 Feb 23
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
19 Jan 23
NeoGenomics Wins Department Of Veterans Affairs Contract 'Specialized Reference Lab Testing'
9 Jan 23
Press releases
INVESTOR REMINDER: NEOGENOMICS, INC. (NASDAQ:NEO). Berger Montague Advises Investors to Inquire About a Securities Fraud Action by February 6, 2023
4 Feb 23
NEOGENOMICS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In NeoGenomics To Contact Him Directly To Discuss Their Options
4 Feb 23
NEOGENOMICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO
3 Feb 23
NEOGENOMICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NeoGenomics, Inc. and Encourages Investors to Contact the Firm
3 Feb 23
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
3 Feb 23